These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1600 related items for PubMed ID: 29372664

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Cardiovascular mortality and morbidity in patients with type 2 diabetes following initiation of sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs (CVD-REAL Nordic): a multinational observational analysis.
    Birkeland KI, Jørgensen ME, Carstensen B, Persson F, Gulseth HL, Thuresson M, Fenici P, Nathanson D, Nyström T, Eriksson JW, Bodegård J, Norhammar A.
    Lancet Diabetes Endocrinol; 2017 Sep; 5(9):709-717. PubMed ID: 28781064
    [Abstract] [Full Text] [Related]

  • 4. Association of Sodium-Glucose Cotransporter 2 Inhibitors With Cardiovascular Outcomes in Patients With Type 2 Diabetes and Other Risk Factors for Cardiovascular Disease: A Meta-analysis.
    Bhattarai M, Salih M, Regmi M, Al-Akchar M, Deshpande R, Niaz Z, Kulkarni A, Siddique M, Hegde S.
    JAMA Netw Open; 2022 Jan 04; 5(1):e2142078. PubMed ID: 34985519
    [Abstract] [Full Text] [Related]

  • 5. Effects of SGLT2 inhibitors on cardiovascular outcomes and mortality in type 2 diabetes: A meta-analysis.
    Zou CY, Liu XK, Sang YQ, Wang B, Liang J.
    Medicine (Baltimore); 2019 Dec 04; 98(49):e18245. PubMed ID: 31804352
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Effect of SGLT2 inhibitors on cardiovascular, renal and safety outcomes in patients with type 2 diabetes mellitus and chronic kidney disease: A systematic review and meta-analysis.
    Toyama T, Neuen BL, Jun M, Ohkuma T, Neal B, Jardine MJ, Heerspink HL, Wong MG, Ninomiya T, Wada T, Perkovic V.
    Diabetes Obes Metab; 2019 May 04; 21(5):1237-1250. PubMed ID: 30697905
    [Abstract] [Full Text] [Related]

  • 9. Cardiovascular outcomes with sodium-glucose cotransporter-2 inhibitors in patients with type II diabetes mellitus: A meta-analysis of placebo-controlled randomized trials.
    Saad M, Mahmoud AN, Elgendy IY, Abuzaid A, Barakat AF, Elgendy AY, Al-Ani M, Mentias A, Nairooz R, Bavry AA, Mukherjee D.
    Int J Cardiol; 2017 Feb 01; 228():352-358. PubMed ID: 27866027
    [Abstract] [Full Text] [Related]

  • 10. Cardiovascular Safety, Long-Term Noncardiovascular Safety, and Efficacy of Sodium-Glucose Cotransporter 2 Inhibitors in Patients With Type 2 Diabetes Mellitus: A Systemic Review and Meta-Analysis With Trial Sequential Analysis.
    Zhang XL, Zhu QQ, Chen YH, Li XL, Chen F, Huang JA, Xu B.
    J Am Heart Assoc; 2018 Jan 20; 7(2):. PubMed ID: 29353233
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials.
    Nuffield Department of Population Health Renal Studies Group, SGLT2 inhibitor Meta-Analysis Cardio-Renal Trialists' Consortium.
    Lancet; 2022 Nov 19; 400(10365):1788-1801. PubMed ID: 36351458
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Glucose-lowering drugs or strategies, atherosclerotic cardiovascular events, and heart failure in people with or at risk of type 2 diabetes: an updated systematic review and meta-analysis of randomised cardiovascular outcome trials.
    Ghosh-Swaby OR, Goodman SG, Leiter LA, Cheng A, Connelly KA, Fitchett D, Jüni P, Farkouh ME, Udell JA.
    Lancet Diabetes Endocrinol; 2020 May 19; 8(5):418-435. PubMed ID: 32333878
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Sodium-glucose co-transporter-2 inhibitors and risk of adverse renal outcomes among patients with type 2 diabetes: A network and cumulative meta-analysis of randomized controlled trials.
    Tang H, Li D, Zhang J, Li Y, Wang T, Zhai S, Song Y.
    Diabetes Obes Metab; 2017 Aug 19; 19(8):1106-1115. PubMed ID: 28240446
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. SGLT2 inhibitors and atrial fibrillation in type 2 diabetes: a systematic review with meta-analysis of 16 randomized controlled trials.
    Li WJ, Chen XQ, Xu LL, Li YQ, Luo BH.
    Cardiovasc Diabetol; 2020 Aug 26; 19(1):130. PubMed ID: 32847602
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 80.